- Home
- DGNX vs MLYS Comparison
DGNX vs MLYS Comparison
Compare DGNX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- MLYS
- Stock Information
- Founded
- DGNX 2018
- MLYS 2019
- Country
- DGNX United Kingdom
- MLYS United States
- Employees
- DGNX N/A
- MLYS N/A
- Industry
- DGNX
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- DGNX
- MLYS Health Care
- Exchange
- DGNX NYSE
- MLYS Nasdaq
- Market Cap
- DGNX 1.2B
- MLYS 1.0B
- IPO Year
- DGNX 2025
- MLYS 2023
- Fundamental
- Price
- DGNX $47.21
- MLYS $15.45
- Analyst Decision
- DGNX
- MLYS Strong Buy
- Analyst Count
- DGNX 0
- MLYS 3
- Target Price
- DGNX N/A
- MLYS $33.00
- AVG Volume (30 Days)
- DGNX 49.3K
- MLYS 866.7K
- Earning Date
- DGNX 01-01-0001
- MLYS 05-12-2025
- Dividend Yield
- DGNX N/A
- MLYS N/A
- EPS Growth
- DGNX N/A
- MLYS N/A
- EPS
- DGNX N/A
- MLYS N/A
- Revenue
- DGNX $1,177,066.00
- MLYS N/A
- Revenue This Year
- DGNX N/A
- MLYS N/A
- Revenue Next Year
- DGNX N/A
- MLYS N/A
- P/E Ratio
- DGNX N/A
- MLYS N/A
- Revenue Growth
- DGNX N/A
- MLYS N/A
- 52 Week Low
- DGNX $3.60
- MLYS $8.24
- 52 Week High
- DGNX $155.00
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- MLYS 55.06
- Support Level
- DGNX N/A
- MLYS $14.75
- Resistance Level
- DGNX N/A
- MLYS $16.11
- Average True Range (ATR)
- DGNX 0.00
- MLYS 0.90
- MACD
- DGNX 0.00
- MLYS -0.07
- Stochastic Oscillator
- DGNX 0.00
- MLYS 46.03
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.